Gunnar Strandberg

Gunnar Strandberg

Auto-generated profile, based on publicly available information

Gunnar Strandberg

Section of Anaesthesia and Intensive Care, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
12 January 2021 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
PDF file
BABjörn Ahlström
Björn Ahlström
RFRobert Frithiof
Robert Frithiof
Michael HultströmMichael Hultström
Michael Hultström
ILIng‐Marie Larsson
Ing‐Marie Larsson
GSGunnar Strandberg
Gunnar Strandberg
MLMiklos Lipcsey
Miklos Lipcsey
Background: Several studies have recently addressed factors associated with severe Coronavirus disease 2019 (COVID‐19); however, some medications and comorbidities have yet to be evaluated in a large matched cohort. We therefore explored the role of relevant comorbidities and medications in relation to the risk of intensive care unit (ICU) admission and mortality.Methods: All ICU COVID‐19 patients in Sweden until 27 May 2020 were matched to population controls on age and gender to assess the risk of ICU admission. Cases were identified, comorbidities and medications were retrieved from high‐quality registries. Three conditional logistic regression models were used for risk of ICU admission and three Cox proportional hazards models for risk of ICU mortality, one with comorbidities, one with medications and finally with both models combined, respectively.Results: We included 1981 patients and 7924 controls. Hypertension, type 2 diabetes mellitus, chronic renal failure, asthma, obesity, being a solid organ transplant recipient and immunosuppressant medications were independent risk factors of ICU admission and oral anticoagulants were protective. Stroke, asthma, chronic obstructive pulmonary disease and treatment with renin‐angiotensin‐aldosterone inhibitors (RAASi) were independent risk factors of ICU mortality in the pre‐specified primary analyses; treatment with statins was protective. However, after adjusting for the use of continuous renal replacement therapy, RAASi were no longer an independent risk factor.Conclusion: In our cohort oral anticoagulants were protective of ICU admission and statins was protective of ICU death. Several comorbidities and ongoing RAASi treatment were independent risk factors of ICU admission and ICU mortality.

30 March 2020 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
PDF file
GSGunnar Strandberg
Gunnar Strandberg
SWSten Walther
Sten Walther
CÖChristina Agvald Öhman
Christina Agvald Öhman
MLMiklos Lipcsey
Miklos Lipcsey
Background: Recent studies have reported substantially decreased hospital mortality for sepsis, but data are scarcer on outcomes after hospital discharge. We studied mortality up to 1 year in Swedish intensive care unit (ICU) patients with and without sepsis.Methods: Demographic and medical data for all registered adult general ICU patients admitted between 01‐01‐2008 and 30‐09‐2016 were retrieved from the Swedish Intensive Care Registry and linked with the National Patient Register for comorbidity data and the Cause of Death Register for death dates. The population was divided in two cohorts; (a) Patients with a diagnosis of severe sepsis or septic shock and (b) All other ICU patients. Crude yearly mortality was calculated, and logistic regression was used to analyse predictors of mortality.Results: 28 886 sepsis and 221 941 nonsepsis ICU patients were identified. In the sepsis cohort, in 2008 unadjusted mortality was 32.6% at hospital discharge, 32.7% at 30 days, 39% at 90 days and 46.8% at 365 days. In 2016, mortality was 30.5% at hospital discharge, 31.9% at 30 days and 38% at 90 days. Mortality at 365 days was 45.3% in 2015. Corresponding nonsepsis mortality was 15.4%, 16.2%, 20% and 26% in 2008 and 15.6%, 17.1%, 20.7% and 26.7% in 2016/2015. No consistent decrease in odds of mortality was seen in the adjusted analysis.Conclusions: Mortality in severe sepsis and septic shock is high, with more than one in three patients not surviving three months after ICU admission, and adjusted mortality has not decreased convincingly in Sweden 2008‐2016.Trial Registration: The study was registered prospectively, ClinicalTrials.gov ID: NCT03489447.

1 November 2012 in Resuscitation
Verified
Journal Article
Closed access
GSGunnar Strandberg
Gunnar Strandberg
MEMats Eriksson
Mats Eriksson
MGMats G. Gustafsson
Mats G. Gustafsson
MLMiklos Lipcsey
Miklos Lipcsey
ALAnders Larsson
Anders Larsson

5 January 2015 in Acta Anaesthesiologica Scandinavica
Verified
Journal Article
Open access
PDF file
GSG. Strandberg
G. Strandberg
ALA. Larsson
A. Larsson
MLMiklos Lipcsey
Miklos Lipcsey
JMJ. Michalek
J. Michalek
MEM. Eriksson
M. Eriksson
Background: We aimed to investigate whether comparable antibiotic concentrations could be reached with intraosseous and intravenous administration during septic shock.Methods: In this randomized, prospective experimental study conducted at an animal research laboratory at the University Hospital of Uppsala, eight anesthetized pigs, weighing 21.2 to 29.1 kg (mean: 25.2 ± 2.3 kg), received endotoxin infusion at 4 μg/kg/h for 6 h. At the onset of clinical shock, alternatively after 3 h of endotoxemia, they received 75 mg/kg of cefotaxime and 7 mg/kg of gentamicin either in a proximal tibial intraosseous catheter or in a peripheral intravenous catheter. Mixed venous samples were taken after 5, 15, 30, 60, 120 and 180 min and analyzed for antibiotic concentrations.Results: For both antibiotics, plasma concentrations after intraosseous and intravenous administration followed similar curves throughout the observation period, and peak concentrations were comparable. Mean concentration area under the curve (AUC mg × h/l) for cefotaxime was 108.1 ± 19.5 after intraosseous and 116.5 ± 11.1 after intravenous administration; ratio 0.93, (95% CI 0.71–1.19). Mean AUC for gentamicin was 28.1 ± 6.8 for intraosseous and 32.2 ± 3.5 for intravenous administration; ratio 0.87 (95% CI 0.62–1.19).Conclusions: In this porcine septic shock model, intraosseous and intravenous administration of gentamicin and cefotaxime yielded comparable concentrations. In an emergency, intraosseous administration of these antibiotics may be considered in severe infections when venous access is difficult.

3 November 2016 in Scandinavian Journal of Trauma, Resuscitation and Emergency Medicine
Verified
Journal Article
Open access
PDF file
GSGunnar Strandberg
Gunnar Strandberg
MLMiklos Lipcsey
Miklos Lipcsey
Mats Bertil ErikssonMats Bertil Eriksson
Mats Bertil Eriksson
NLNorbert Lubenow
Norbert Lubenow
Anders Olof LarssonAnders Olof Larsson
Anders Olof Larsson
Laboratory analysis of coagulation is often important in emergencies. If vascular access is challenging, intraosseous catheterization may be necessary for treatment. We studied the analysis of coagulation parameters in intraosseous aspirate during stable conditions and after major haemorrhage in a porcine model. Ten anesthetized pigs received central venous and intraosseous catheters and samples were taken for analysis of thromboelastography (TEG), prothrombin time (PT), activated partial thromboplastin time (APTT) and fibrinogen concentration. Analyses were repeated after removal of 50 % of the calculated blood volume and resuscitation with crystalloid. Intraosseous and venous values were compared. Bleeding and resuscitation resulted in haemodilution and hypotension. Median TEG reaction time was shorter in intraosseous than in venous samples before (1.6 vs 4.6 min) and after (1.6 vs 4.7 min) haemodilution. Median maximal amplitude was smaller in intraosseous samples at baseline (68.3 vs 76.4 mm). No major differences were demonstrated for the other TEG parameters. The intraosseous samples often coagulated in vitro, making analysis of PT, APTT and fibrinogen difficult. After haemodilution, TEG maximal amplitude and α-angle, and fibrinogen concentration, were decreased and PT increased. The intraosseous samples were clinically hypercoagulable and the TEG demonstrated a shortened reaction time. The reason for this may hypothetically be found in the composition of the IO aspirate or in the sampling technique. After 50 % haemorrhage and haemodilution, a clinically relevant decrease in fibrinogen concentration and a lower TEG maximal amplitude were observed. Although the sample is small, these data indicate that intraosseous samples are hypercoagulable, which may limit their usefulness for coagulation studies. Major haemodilution only moderately affected the studied parameters.